Ashkan Shoamanesh1, Lesly A Pearce2, Carlos Bazan3, Luciana Catanese4, Leslie A McClure5, Mukul Sharma1, Joan Marti-Fabregas6, David C Anderson7, Carlos S Kase8, Robert G Hart1, Oscar R Benavente9. 1. McMaster University and Population Health Research Institute, Hamilton, Ontario, Canada. 2. Biostatistics Consultant, Minot, ND. 3. University of Texas Health Sciences Center, San Antonio, TX. 4. Harvard Medical School, Boston, MA. 5. Drexel University, Philadelphia, PA. 6. Hospital of the Holy Cross and Saint Paul (Biomedical Research Institute, IIB Saint Paul), Barcelona, Spain. 7. Department of Neurology, University of Minnesota, Minneapolis, MN. 8. Boston University School of Medicine, Boston, MA. 9. Brain Research Center, University of British Columbia, Vancouver, British Columbia, Canada.
Abstract
OBJECTIVE: To characterize cerebral microbleeds (CMBs) in lacunar stroke patients in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial and to assess their relationship with recurrent stroke and death, and response to assigned treatment. METHODS: SPS3 is a randomized, clinical trial conducted between 2003 and 2011. Patients with recent magnetic resonance imaging (MRI)-documented lacunar infarcts were randomly assigned in a factorial design to target levels of systolic blood pressure (130-149mmHg vs <130mmHg; open label) and to antiplatelet treatment (aspirin/clopidogrel vs aspirin/placebo; double-blinded). The current analysis involves 1,278 trial participants who had a baseline axial T2*-weighted gradient echo MRI sequence allowing for CMB detection. RESULTS:CMBs were present in 30% of 1,278 patients (mean age = 63 years). Male gender (odds ratio [OR] = 1.7, 95% confidence interval [CI] = 1.3-2.3), history of hypertension (OR = 1.6, 95% CI = 1.2-2.3), increased systolic blood pressure (1.2 per 20mmHg, 95% CI = 1.1-1.4), nondiabetic status (OR = 1.4, 95% CI = 1.1-1.9), multiple old lacunar infarcts (OR = 1.9, 95% CI = 1.5-2.5), and moderate (OR = 1.7, 95% CI = 1.2-2.3) or severe (OR = 4.2, 95% CI = 3.0-5.9) white matter hyperintensities on MRI were independently associated with CMBs. During a mean follow-up of 3.3 years, overall stroke recurrence was 2.5% per patient-year. Patients with CMBs had an adjusted 2-fold increased risk of recurrent stroke (hazard ratio = 2.1, 95% CI = 1.4-3.1). CMBs were not a risk factor for death. There were no statistically significant interactions between CMBs and treatment assignments. INTERPRETATION:Patients with lacunar stroke and CMBs likely harbor a more advanced form of cerebral small vessel disease in need of efficacious therapeutic strategies. Ann Neurol 2017;82:196-207.
RCT Entities:
OBJECTIVE: To characterize cerebral microbleeds (CMBs) in lacunar strokepatients in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial and to assess their relationship with recurrent stroke and death, and response to assigned treatment. METHODS:SPS3 is a randomized, clinical trial conducted between 2003 and 2011. Patients with recent magnetic resonance imaging (MRI)-documented lacunar infarcts were randomly assigned in a factorial design to target levels of systolic blood pressure (130-149mmHg vs <130mmHg; open label) and to antiplatelet treatment (aspirin/clopidogrel vs aspirin/placebo; double-blinded). The current analysis involves 1,278 trial participants who had a baseline axial T2*-weighted gradient echo MRI sequence allowing for CMB detection. RESULTS:CMBs were present in 30% of 1,278 patients (mean age = 63 years). Male gender (odds ratio [OR] = 1.7, 95% confidence interval [CI] = 1.3-2.3), history of hypertension (OR = 1.6, 95% CI = 1.2-2.3), increased systolic blood pressure (1.2 per 20mmHg, 95% CI = 1.1-1.4), nondiabetic status (OR = 1.4, 95% CI = 1.1-1.9), multiple old lacunar infarcts (OR = 1.9, 95% CI = 1.5-2.5), and moderate (OR = 1.7, 95% CI = 1.2-2.3) or severe (OR = 4.2, 95% CI = 3.0-5.9) white matter hyperintensities on MRI were independently associated with CMBs. During a mean follow-up of 3.3 years, overall stroke recurrence was 2.5% per patient-year. Patients with CMBs had an adjusted 2-fold increased risk of recurrent stroke (hazard ratio = 2.1, 95% CI = 1.4-3.1). CMBs were not a risk factor for death. There were no statistically significant interactions between CMBs and treatment assignments. INTERPRETATION:Patients with lacunar stroke and CMBs likely harbor a more advanced form of cerebral small vessel disease in need of efficacious therapeutic strategies. Ann Neurol 2017;82:196-207.
Authors: Charlotte Cordonnier; Gillian M Potter; Caroline A Jackson; Fergus Doubal; Sarah Keir; Cathie L M Sudlow; Joanna M Wardlaw; Rustam Al-Shahi Salman Journal: Stroke Date: 2008-11-13 Impact factor: 7.914
Authors: Andrew Dumas; Gregory A Dierksen; M Edip Gurol; Amy Halpin; Sergi Martinez-Ramirez; Kristin Schwab; Jonathan Rosand; Anand Viswanathan; David H Salat; Jonathan R Polimeni; Steven M Greenberg Journal: Ann Neurol Date: 2012-07 Impact factor: 10.422
Authors: Irmhild Altmann-Schneider; Stella Trompet; Anton J M de Craen; Adriaan C G M van Es; J Wouter Jukema; David J Stott; Naveed Sattar; Rudi G J Westendorp; Mark A van Buchem; Jeroen van der Grond Journal: Stroke Date: 2011-01-13 Impact factor: 7.914
Authors: Wouter J Schonewille; Michael B Singer; Scott W Atlas; Stanley Tuhrim Journal: J Stroke Cerebrovasc Dis Date: 2005 Jul-Aug Impact factor: 2.136
Authors: Brian Mac Grory; Shadi Yaghi; Charlotte Cordonnier; Luciano A Sposato; Jose G Romano; Seemant Chaturvedi Journal: Circ Res Date: 2022-04-14 Impact factor: 23.213
Authors: Andreas Charidimou; Sara Shams; Jose R Romero; Jie Ding; Roland Veltkamp; Solveig Horstmann; Gudny Eiriksdottir; Mark A van Buchem; Vilmundur Gudnason; Jayandra J Himali; M Edip Gurol; Anand Viswanathan; Toshio Imaizumi; Meike W Vernooij; Sudha Seshadri; Steven M Greenberg; Oscar R Benavente; Lenore J Launer; Ashkan Shoamanesh Journal: Int J Stroke Date: 2018-01-17 Impact factor: 5.266
Authors: Ashkan Shoamanesh; Andrea Morotti; Javier M Romero; Jamary Oliveira-Filho; Frieder Schlunk; Michael J Jessel; Alison M Ayres; Anastasia Vashkevich; Kristin Schwab; Mohammad R Afzal; Christy Cassarly; Renee H Martin; Adnan I Qureshi; Steven M Greenberg; Jonathan Rosand; Joshua N Goldstein Journal: JAMA Neurol Date: 2018-07-01 Impact factor: 18.302
Authors: Rustam Al-Shahi Salman; David P Minks; Dipayan Mitra; Mark A Rodrigues; Priya Bhatnagar; Johann C du Plessis; Yogish Joshi; Martin S Dennis; Gordon D Murray; David E Newby; Peter A G Sandercock; Nikola Sprigg; Jacqueline Stephen; Cathie L M Sudlow; David J Werring; William N Whiteley; Joanna M Wardlaw; Philip M White Journal: Lancet Neurol Date: 2019-05-22 Impact factor: 59.935